Rivoceranib
- Generic Name
- Rivoceranib
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23N5O
- CAS Number
- 811803-05-1
- Unique Ingredient Identifier
- 5S371K6132
- Background
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
- Indication
本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。
Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT06200233
- Locations
- 🇰🇷
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of
Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-01-03
- Target Recruit Count
- 37
- Registration Number
- NCT06188455
A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies
- Conditions
- Biliary Tract Malignancies
- Interventions
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2024-04-30
- Target Recruit Count
- 35
- Registration Number
- NCT06181032
- Locations
- 🇨🇳
The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
Tucidinostat Plus Apatinib for Advanced Osteosarcoma
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 46
- Registration Number
- NCT06125171
KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
- Conditions
- Digestive System Cancers
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 39
- Registration Number
- NCT06099821
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, China
Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment
- Conditions
- Relapsed Ovarian Cancer
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Jin Li
- Target Recruit Count
- 54
- Registration Number
- NCT06081595
Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer
- Conditions
- NSCLCNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 60
- Registration Number
- NCT05932264
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 48
- Registration Number
- NCT05905887
- Locations
- 🇰🇷
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2023-05-11
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 244
- Registration Number
- NCT05854849
- Locations
- 🇨🇳
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2023-05-10
- Target Recruit Count
- 30
- Registration Number
- NCT05853172
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.